ERBB2 and breast carcinoma: The two novel ceRNA networks (LINC00589/miR-100/DLG5 and LINC00589/miR-452/PRDM16) may be exploited as useful prognostic markers and novel therapeutic targets for drug-refractory HER2-positive breast cancer.